Kymera Shares Soar After Faster-Than-Expected Trial Enrollment Moves Key Data Up Six Months
Kymera Therapeutics rallied sharply in morning trading after the company said it had finished enrolling patients in its BROADEN2 Phase 2b study of KT-621, an oral STAT6 degrader for moderate-to-severe atopic dermatitis, nearly six months ahead of schedule. The accelerated enrollment shifts the anticipated topline readout to year-end 2026 and suppor…